MA45240A - Forme galénique à unités multiples comprenant un noyau avec des unités de noyau individuelles recouvertes d'un matériau muco-adhésif, et un enrobage de noyau entérique - Google Patents

Forme galénique à unités multiples comprenant un noyau avec des unités de noyau individuelles recouvertes d'un matériau muco-adhésif, et un enrobage de noyau entérique

Info

Publication number
MA45240A
MA45240A MA045240A MA45240A MA45240A MA 45240 A MA45240 A MA 45240A MA 045240 A MA045240 A MA 045240A MA 45240 A MA45240 A MA 45240A MA 45240 A MA45240 A MA 45240A
Authority
MA
Morocco
Prior art keywords
core
muco
adhesive material
enteric
shape consisting
Prior art date
Application number
MA045240A
Other languages
English (en)
Inventor
Roberto Bravo
Daniel Preisig
Felipe Varum
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MA45240A publication Critical patent/MA45240A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045240A 2016-06-14 2017-06-12 Forme galénique à unités multiples comprenant un noyau avec des unités de noyau individuelles recouvertes d'un matériau muco-adhésif, et un enrobage de noyau entérique MA45240A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16174466.9A EP3257501A1 (fr) 2016-06-14 2016-06-14 Forme galénique unitaire multiple comprenant un noyau avec différentes unités de coeur recouvertes par un matériau muco-adhésif et un revêtement noyau gastro-résistant

Publications (1)

Publication Number Publication Date
MA45240A true MA45240A (fr) 2019-04-17

Family

ID=56131433

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045240A MA45240A (fr) 2016-06-14 2017-06-12 Forme galénique à unités multiples comprenant un noyau avec des unités de noyau individuelles recouvertes d'un matériau muco-adhésif, et un enrobage de noyau entérique

Country Status (9)

Country Link
US (1) US20190336449A1 (fr)
EP (2) EP3257501A1 (fr)
JP (1) JP2019518758A (fr)
AR (1) AR108729A1 (fr)
CA (1) CA3026840A1 (fr)
MA (1) MA45240A (fr)
TW (1) TW201742621A (fr)
UY (1) UY37293A (fr)
WO (1) WO2017216088A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434109A (zh) * 2018-04-25 2018-08-24 首都医科大学附属北京儿童医院 微型巯嘌呤片、微型巯嘌呤肠溶缓释片、及其制备方法
EP3613414A1 (fr) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Granulés à structure multicouche permettant la libération retardée de la substance active dans le colon distal
MX2021002686A (es) * 2018-09-06 2021-08-11 Fachhochschule Nordwestschweiz Formulacion controlada de liberacion de farmacos.
CN112770730B (zh) * 2018-09-06 2024-02-13 瑞士西北应用科学与艺术大学 受控的药物释放制剂
EP3662901A1 (fr) * 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation de medicaments a liberation ranlentie avec une couche exterieure comprenant un polymere degradable par des enzymes, sa composition et son processus de production
TW202308652A (zh) * 2021-04-20 2023-03-01 大陸商江蘇恒瑞醫藥股份有限公司 用於藥物特定遞送的膠囊及其製備方法
WO2024200722A1 (fr) * 2023-03-28 2024-10-03 Tillotts Pharma Ag Forme pharmaceutique solide orale composée d'anticorps pour libération prolongée dans le tractus digestif inférieur

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4627851A (en) 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
BRPI0706280A2 (pt) * 2006-01-05 2011-03-22 Lifecycle Pharma As produto de comprimido carregável desintegrante, e, método para a preparação de um comprimido carregável desintegrante
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
SI2152250T1 (sl) 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
EP2168572A1 (fr) 2008-09-30 2010-03-31 Omya Development Ag Nouveau support d'agent actif à libération contrôlée
EP2264108B1 (fr) 2009-06-15 2012-02-15 Omya Development AG Procédé pour la préparation d'un carbonate de calcium réagi en surface utilisant un acide faible
JOP20200144A1 (ar) 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
EP3062776A1 (fr) 2013-10-29 2016-09-07 Tillotts Pharma AG Formulation médicamenteuse à libération retardée

Also Published As

Publication number Publication date
WO2017216088A1 (fr) 2017-12-21
JP2019518758A (ja) 2019-07-04
US20190336449A1 (en) 2019-11-07
UY37293A (es) 2018-01-02
AR108729A1 (es) 2018-09-19
TW201742621A (zh) 2017-12-16
CA3026840A1 (fr) 2017-12-21
EP3257501A1 (fr) 2017-12-20
EP3468538A1 (fr) 2019-04-17

Similar Documents

Publication Publication Date Title
MA45240A (fr) Forme galénique à unités multiples comprenant un noyau avec des unités de noyau individuelles recouvertes d'un matériau muco-adhésif, et un enrobage de noyau entérique
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
EP3985601C0 (fr) Système de gestion de jetons de jeu et jeton de jeu correspondant
MA50201A (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
TH170275A (th) วิธีการของการผลิตแคปซูลชนิดนิ่มแบบเอนเทอริก
UA35348S (uk) Набір карток для інтелектуальної гри «гра сенсів»
TH71181S1 (th) อุปกรณ์กายภาพบำบัด
TH174749S (th) อุปกรณ์กายภาพบำบัด
UA37867S (uk) Каблучка «дві клюшки»
TH1701007724A (fr)
UA36047S (uk) Гра «пятнашки»
TH1501005347A (th) องค์ประกอบทางเภสัชกรรมของเอส-คีตามีน ไฮโดรคลอไรด์
TH174273A (th) N-(4-ไฮดรอกซี-4-เมทธิล-ไซโคลเฮกซิล)-4-ฟีนิล-เบนซีนซัลโฟนาไมด์ และ n- (4-ไฮดรอกซี-4-เมทธิล-ไซโคลเฮกซิล)-4-(2-ไพริดิล)เบนซีนซัลโฟนาไมด์ และ การใช้ทางการรักษาโรคของพวกมัน
TH75679S1 (th) เครื่องมือทางการแพทย์
TH186430S (th) เครื่องมือทางการแพทย์
TH1601002264A (th) ส่วนผสมจากสารสกัดจักรนารายณ์และกรรมวิธีการผลิต
TH1701003406A (th) สูตรผสมทางเภสัชกรรมของตัวยับยั้งไคเนสที่เกี่ยวข้องกับโทรโปไมโอซิน(trk)
TH181796A (th) แองจิโอโพอิติน-ไลค์ 4 แอนติบอดี และวิธีการของการใช้
TH181995A (th) เฮเทอโรเอริลไดไฮโดรไพริมิดีนซึ่งถูกหลอมรวม-6 ที่ใหม่ สำหรับการรักษาและ การป้องกันโรคของการติดเชื้อไวรัสตับอักเสบ b
TH174029S (th) กางเกงผ้าอ้อม
TH180317A (th) ส่วนสร้างหลอมของส่วนแอนติซีรัมอัลบูมิน fab-เอฟเฟกเตอร์, และวิธีการเตรียมของมัน
TH1701006801A (th) เฮทเทอโรไซคลิกเอไมด์ ซึ่งเป็นสารยับยั้งไคเนส
TH171414A (th) วิธีการของการผลิตแคปซูลชนิดอ่อนไร้รอยต่อสำหรับลำไส้เล็ก
TH181268A (th) สารยับยั้งแมคโครไซคลิก rip2 ไคเนส
TH179122A (th) แอนติบอดีต้าน cll-1 และอิมมูโนคอนจูเกต